T. Rowe Price Associates’s Cidara Therapeutics CDTX Stock Holding History

T. Rowe Price Associates’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,743	Closed	-$4.36M	–	3144
2025 Q4	$4.36M	Buy	19,743 +11,219	+132%	+$1.81M	﹤0.01%	1433
2025 Q3	$817K	Buy	8,524 +120	+1%	+$7.66K	﹤0.01%	2149
2025 Q2	$410K	Buy	+8,404	New	+$202K	﹤0.01%	2393

T. Rowe Price Associates's CDTX Position: Q1 2026 in Review

T. Rowe Price Associates sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 19,743 shares — an estimated $4.36M sold.

T. Rowe Price Associates first reported a position in CDTX in Q2 2025 and held it in 3 quarters. The position peaked at $4.36M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

T. Rowe Price Associates reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
T. Rowe Price Associates sold 19,743 Cidara Therapeutics shares in Q1 2026, an estimated $4.36M.
T. Rowe Price Associates first reported a position in Cidara Therapeutics in Q2 2025 and held it in 3 quarters.
T. Rowe Price Associates's Cidara Therapeutics position peaked at $4.36M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.